How We Think - Immuno-oncology

These are the posts from the How we think section that have been tagged with Immuno-oncology.

To see all tags used in our posts, click here.

The dark side of direct-to-consumer genetic tests

Natasha Cowan|28th September 2018

Direct-to-consumer testing is an affordable way to better understand your DNA, but is this a leap forward in innovation or another layer clouding an already complex market? From anxious patients to unnecessary surgeries, we reveal the barriers for healthcare professionals and patients, and how to solve these industry challenges.

read more

Medical information in precision medicine

Natasha Cowan|14th June 2018

Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine.

 

read more

Is the pharma business model ready for precision medicine?

Fred Bassett|11th June 2018

Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health Co-founder and Head of Strategy Fred Bassett explores the challenges and opportunities while introducing the latest issue of 'Perspective' magazine on this weighty topic.

read more

Perspective on biotech leaders

Blue Latitude Health|27th November 2017

Seven industry trailblazers reveal the trends, challenges and opportunities they anticipate in the biotech sector, from empowering patients to deciphering big data. 

 

read more

How do you define a biotech company?

David Cooney|6th October 2017

We ask if the defnition of biotech needs updating as big pharma turns its research and development aims to biological therapies.

read more

Emerging technologies in biotech

Ditte Funding, Natasha Cowan|25th September 2017

Associate Consultant Ditte Funding and Content Marketing Executive Natasha Cowan explore the transformative technologies revolutionising the biotech industry, from CAR-T to CRISPR.

read more

Perspective on biotech

Blue Latitude Health|14th September 2017

In this supplementary issue of Perspective, we reveal the emerging technologies taking the biotech world by storm and ask if the definition of a biotech organisation needs updating

read more

Molecules in a particle-based vaccine for cancer therapy

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

Frances Hendry|19th May 2017

Anne Legendre reviews the scientific rationale behind immunotherapy combinations and Frances Hendry examines how partnerships, co-marketing and positioning drugs will play key roles in shaping the competitive landscape in oncology.

read more

chessboard-strategy-photo

Marketing strategy in complex environments

Mark Assenti, Kulveer Singh|19th September 2016

Age-old treatment protocols are being replaced with new and innovative treatment paradigms that will revolutionise the healthcare industry for years to come. Kulveer Singh and Mark Assenti talk through what this means for pharma strategists and their product lines.

read more

Stumble-but-not-a-fall-whats-next-for-opdivo-feature-image

A stumble, but not a fall – what’s next for Opdivo?

Louis Perdios|24th August 2016

In this article, Associate Consultant Louis Perdios talks about the immunotherapy drug Opdivo and the daunting challenges faced by BMS after disappointing results. However the future for Opdivo may not be as bleak as it seems. 

 

read more

The landscape of healthcare has changed. So have we.

Blue Latitude Health is now Fishawack Health

Discover fishawack.com
Redirecting you to fishawack.com in 5...